Biocon Share Price: Biocon shares surged 5.4% after FDA classified its Bengaluru facility as Voluntary Action Indicated (VAI). The stock is...

Biocon Biologics received EMA approval to manufacture biosimilar Bevacizumab in Bengaluru, providing additional capacity to address patient...

Biocon Limited announced that its wholly-owned subsidiary, Biocon Generics Inc., has acquired Eywa Pharma Inc.’s oral solid dosage manufact...

Improving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when an in...

The USFDA conducted three on-site inspections of Biocon Biologics' seven manufacturing facilities spanning two sites in Bengaluru, India an...

The company's new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru has received the certif...

The EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. As per the USFDA, a VAI mean...

Banks were among the top drivers of the rally, with ICICI Bank rallying 5% and SBI 3.5%.

India’s leading drug companies have had their manufacturing facilities cleared in the last 10 days by the US Food and Drug Administration (...

Biocon is confident of addressing these expeditiously and remains committed to global standards of quality and compliance, the statement ad...

The facility, set up with an investment of $275 million, is designed to manufacture recombinant human insulin and insulin analogs for the g...

Biocon shares tanked 5.9 per cent to Rs 328.80 at the close on the BSE on Wednesday.

ANSM has raised deficiencies concerning two biosimilar products intended in the treatment of cancer and one intended for diabetes.

Speaking to ET, GS Krishnan, Regional President, Novozymes India said among other things, the new site is expected to help meet requirement...

At the event, Sajjan Jindal, the managing director of JSW Steel announced a Rs 35,000 crore investment in the state.

Shaw was immediately perceived as the face of corporate India and the Congress trolls swung into action, painting her stand as anti-farmer.